PMA device
ColoSense®
Geneoscopy, Inc. · System, Colorectal Neoplasia, Rna Markers And Hemoglobin Detection (SBB, Class III) · First FDA decision May 3, 2024, newest Aug 27, 2026Colorectal cancer and polyps
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
Breakthrough-designated
Device trials
1
Naming "ColoSense"
MAUDE reports
0
Brand "ColoSense", since 2015
PubMed studies
5
Mentioning "ColoSense"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ColoSense®
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- ColoSense®PMA supplement
P230001-S012 · Decided Aug 27, 2026 · 209 days after receipt · Normal 180 Day Track
Device type: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection (SBB) · Laboratory Medicine & Pathology
- ColoSense®PMA supplement
P230001-S008 · Decided Jul 3, 2025 · 155 days after receipt · Normal 180 Day Track No User Fee
Device type: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection (SBB) · Laboratory Medicine & Pathology
- ColoSensePMA supplement
P230001-S005 · Decided May 14, 2025 · 264 days after receipt · Normal 180 Day Track
Device type: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection (SBB) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Colorectal Cancer-Non-Invasive Biomarker TestsNational analysisReview closedCAG-00440RUpdated Sep 22, 2026
- Screening for Colorectal Cancer - Blood-Based Biomarker TestsNational analysisReview closedCAG-00454NUpdated Sep 22, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38678WPS Insurance CorporationUpdated Jun 18, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38584CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39276CGS Administrators, LLCUpdated Feb 13, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38643Noridian Healthcare Solutions, LLCUpdated Jan 26, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39262Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Phenotypic Biomarker Detection in Circulating Tumor CellsLocal determinationIn effectL38566Palmetto GBAUpdated Jun 24, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "ColoSense", any status and sponsor, newest update first.
- ColoSense Post-Approval StudyRecruiting
Geneoscopy, Inc.Not on our public-company list
NCT07069556 · 12,500 participants (planned) · Start Sep 5, 2025 · Primary completion Sep 1, 2028
Device: ColoSense · For: Colorectal Cancer (Diagnosis)
Sites: St Louis, Missouri
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ColoSense", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SBB
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- ColoSense Test Kit, Part No. 80-001, component of ColoSense testOpen, Classified
Z-2077-2025 · Started May 20, 2025 · Posted by FDA Jul 3, 2025
Reason given: Multiple plate failures documented as a result of the Low Positive Template Control being too high and out of range using the affected lot of ColoSense Test Kit.
Cause as FDA categorized it: Unknown/Undetermined by firm · Device type: System, Colorectal Neoplasia, Rna Markers And Hemoglobin Detection (SBB)
Published research
The most relevant PubMed records for "ColoSense"[tiab]. The summary above synthesizes these.
- Multitarget Stool RNA Test for Colorectal Cancer Screening.
Barnell EK, Wurtzler EM, La Rocca J, et al. · JAMA · 2023Clinical Trial, Phase III, Comparative Study
- Analytical Validation of the Multitarget Stool RNA Test for Colorectal Cancer Screening.
Barnell EK, Land J, Kruse K, et al. · J Mol Diagn · 2024Validation Study
- Cost-Effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia.
Shaukat A, Levin TR, Liang PS, et al. · Clin Gastroenterol Hepatol · 2026
- Analytical validation of a scrape-free multitarget stool RNA test for colorectal cancer screening.
Barnell EK, Kruse K, Wurtzler EM, et al. · Pract Lab Med · 2025
- FIT and molecular tests versus colonoscopy: an economic evaluation of colorectal cancer screening in the United States.
Chang Y, Hao S, Mao M · Front Oncol · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.